Cana­di­an star re­searcher Bren­dan Frey bran­dish­es Deep Ge­nomic­s' first AI-dis­cov­ered drug

A start­up har­ness­ing AI in drug dis­cov­ery has put for­ward its first ther­a­peu­tic can­di­date — and it may not be who you’re think­ing.

To be sure, Deep Ge­nomics still has a ways to go in pre­lim­i­nary an­i­mal work to en­sure safe­ty and non-hu­man pri­mate as well as biodis­tri­b­u­tion be­fore they can move in­to clin­i­cal test­ing. But the fact that its AI sys­tem was able to go from tar­get iden­ti­fi­ca­tion to de­clar­ing a win­ner in 18 months, said CEO Bren­dan Frey, is a game-chang­er.

Frey found­ed Deep Ge­nomics in Toron­to in 2014, a cou­ple years af­ter more well-known play­ers such as Atom­wise, Benev­o­len­tAI and Re­cur­sion popped up, based on a decade of re­search on how AI can help sci­en­tists un­der­stand ge­net­ic dis­eases. While oth­er plat­forms have tend­ed to ze­ro in on one part of the puz­zle — Atom­wise is fo­cused on ac­cel­er­at­ing small mol­e­cule screen­ing, Re­cur­sion re­lies on cell imag­ing, and in­sil­i­co us­es AI to mod­i­fy ex­ist­ing drugs — its tech “does the whole thing.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER